Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01290
Abstract: The proprotein convertase subtilisin/kexin-type 9 (PCSK9) binds to low-density lipoprotein receptors (LDLR), thereby trafficking them to lysosomes upon endocytosis and enhancing intracellular degradation to prevent their recycling. As a result, the levels of circulating LDL… read more here.
Keywords: pcsk9 inhibitors; inhibitors hypercholesterolemia; development pcsk9; pcsk9 ... See more keywords